Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports

Epidermal growth factor receptor (EGFR) mutations are common in lung adenocarcinoma (ADC) but rare in squamous cell carcinoma (SQC). The efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for SQC with EGFR mutations is unclear. The aim of this study was to evaluate the efficacy of EGFR-TKIs for...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yongmei, Zhang, Yan, Zhang, Li, Liu, Bin, Wang, Yongsheng, Zhou, Xiaojuan, Li, Yanying, Zhao, Qian, Gong, Youling, Zhou, Lin, Zhu, Jiang, Ding, Zhenyu, Wang, Jin, Peng, Feng, Huang, Meijuan, Li, Lu, Ren, Li, Lu, You
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564798/
https://www.ncbi.nlm.nih.gov/pubmed/28591695
http://dx.doi.org/10.18632/oncotarget.17915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564798/
https://www.ncbi.nlm.nih.gov/pubmed/28591695
http://dx.doi.org/10.18632/oncotarget.17915

Ejemplares similares